Quest Diagnostics (DGX) Tops Q4 EPS by 4c; Guides In-Line

Quest Diagnostics (NYSE: DGX) reported Q4 EPS of $1.31, $0.04 better than the analyst estimate of $1.27. Revenue for the quarter came in at $1.86 billion versus the consensus estimate of $1.86 billion.

GUIDANCE:

Quest Diagnostics sees FY2017 EPS of $5.37-$5.52, versus the consensus of $5.45. Quest Diagnostics sees FY2017 revenue of $7.64-7.72 billion, versus the consensus of $7.66 billion.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• lululemon athletica (LULU) Tops Q2 EPS by $1.10, Cuts Guidance
• UiPath Inc. (PATH) Reports In-Line Q2 EPS; offers guidance